Biopharma and Health Related News

Indee Labs secures funding to develop unique gene therapy manufacturing technology in Australia

Biomedtech Horizons Project Will See Cancer-Curing Gene Therapies Manufactured For The Masses 6:30pm AEST, Tuesday 17 April, Melbourne, Australia – MTPConnect and the Minister for Health, the Hon Greg Hunt MP, today announced that Indee Labs will receive grant funding of nearly A$1M [...]

Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS

Major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine development and manufacturing on two of CEPI’s highest priority infectious diseases PLYMOUTH MEETING, Pa. and OSLO, Norway, April 11, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and CEPI – the [...]

Science Exchange and Ranomics Collaborate to Offer Online Access to their VariantFindTM Mutagenesis Platform

April 09, 2018 08:33 AM Eastern Daylight Time PALO ALTO, Calif.--(BUSINESS WIRE)--Science Exchange, the world's leading and most secure enterprise platform for outsourced research and development services, announced a collaboration with Ranomics to offer online access to its mutagenesis platform to [...]

Poseida Raises $30.5 Million in Series B Financing

SAN DIEGO – April 3, 2018 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced the company has raised $30.5 million in an oversubscribed Series B financing round, led by Longitude Capital. [...]

Synlogic Announces Registered Direct Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 6, 2018-- Synlogic, Inc.(Nasdaq: SYBX), a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that it has agreed to sell 3,280,000 shares of its common stock to a large mutual fund investor in [...]

Synlogic Doses First Patient in Phase 1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis

– First clinical trial of a Synthetic Biotic™Medicine in patients – – Randomized, double-blind, placebo-controlled study evaluating safety and tolerability of SYNB1020 as primary endpoint; ammonia-lowering as secondary endpoint – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 2, 2018-- Synlogic (Nasdaq:SYBX), a clinical-stage company applying synthetic biology to [...]